Press release
B-Cell Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis, DelveInsight | Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi Biomedicine
B-Cell Lymphoma Pipeline Insights
B-Cell Lymphoma Overview:
B-cell lymphoma is a form of non-Hodgkin lymphoma (NHL) that develops from B lymphocytes, a type of white blood cell responsible for producing antibodies to combat infections. Representing approximately 85% of all NHL cases, B-cell lymphomas include various subtypes such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma. While each subtype has unique clinical characteristics, they are generally marked by the abnormal growth of B-cells in the lymphatic system, often affecting the lymph nodes, spleen, and bone marrow.
Request for a detailed insights report on B-Cell Lymphoma pipeline insights @ https://www.delveinsight.com/report-store/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"B-Cell Lymphoma Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the B-Cell Lymphoma Therapeutics Market.
Key Takeaways from the B-Cell Lymphoma Pipeline Report
DelveInsight's B-Cell Lymphoma pipeline report depicts a robust space with 295+ active players working to develop 300+ pipeline therapies for B-Cell Lymphoma treatment.
In May 2023, Bristol Myers Squibb reported positive topline results from two studies: TRANSCEND FL, a global Phase 2, open-label, multicenter, single-arm study of Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001, a pivotal Phase 1, open-label, multicenter, single-arm study of Breyanzi in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), including mantle cell lymphoma (MCL). Both studies met their primary endpoint of overall response rate, with Breyanzi showing statistically significant and clinically meaningful responses in relapsed or refractory FL and MCL.
In May 2023, Janssen Biotech, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies.
In May 2023, Genmab A/S announced that the U.S. Food and Drug Administration (FDA) approved EPKINLY™ (epcoritamab-bysp), the first and only T-cell engaging bispecific antibody for treating adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma and high-grade B-cell lymphoma, after two or more lines of systemic therapy.
In January 2023, Fate Therapeutics, Inc. announced it had declined a proposal from Janssen Biotech, Inc. to continue their collaboration and option agreement under revised terms. As a result, the agreement was terminated, and all collaboration activities were set to wind down by the first quarter of 2023.
Key B-Cell Lymphoma companies such as Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi Biomedicine GmbH, AVM Biotechnology, Lin BioScience, Inc, Incyte Corporation, ADC Therapeutics S.A., Genor Biopharma, Beijing InnoCare Pharma Tech Co., Ltd., CARGO Therapeutics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., SystImmune, LIBO PHARMA, Abclon, BeiGene, Cellectis, Iovance Biotherapeutics, Inc., Guangzhou Excelmab, Y-mAbs Therapeutics, TG Therapeutics, Sutro Biopharma, AbbVie, Aleta Biotherapeutics, Janssen Research & Development, LLC, Lantern Pharma, Beijing Immunochina Medical Science and Technology, Bantam Pharmaceutical, Lin Bioscience, SFA Therapeutics, neoX Biotech, March Biosciences, HUTCHMED, and others are evaluating new drugs for B-Cell Lymphoma to improve the treatment landscape.
Promising B-Cell Lymphoma pipeline therapies in various stages of development include Lisocabtagene maraleucel, Glofitamab, NKTR-255, Zamtocabtagene autoleucel, MB-CART20.1, AVM0703, LBS-007, and others.
B-Cell Lymphoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the B-Cell Lymphoma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-Cell Lymphoma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the B-Cell Lymphoma market.
Download our free sample page report on B-Cell Lymphoma pipeline insights @ https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
B-Cell Lymphoma Emerging Drugs
Lisocabtagene maraleucel: Bristol Myers Squibb
Glofitamab: Hoffmann-La Roche
NKTR-255: Nektar Therapeutics
Zamtocabtagene autoleucel: Miltenyi Biomedicine GmbH
MB-CART20.1: Miltenyi Biomedicine GmbH
AVM0703: AVM Biotechnology
LBS-007: Lin BioScience, Inc
B-Cell Lymphoma Companies
Over 295 leading companies are working on therapies for B-cell lymphoma. Among them, Denovo BioPharma has drug candidates in the most advanced stage of development, Phase III.
DelveInsight's report covers around 295+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
B-Cell Lymphoma Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging B-Cell Lymphoma Therapies and Key Companies: B-Cell Lymphoma Clinical Trials and advancements @ https://www.delveinsight.com/report-store/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
B-Cell Lymphoma Pipeline Therapeutic Assessment
• B-Cell Lymphoma Assessment by Product Type
• B-Cell Lymphoma By Stage
• B-Cell Lymphoma Assessment by Route of Administration
• B-Cell Lymphoma Assessment by Molecule Type
Download B-Cell Lymphoma Sample report to know in detail about the B-Cell Lymphoma treatment market @ B-Cell Lymphoma Therapeutic Assessment @ https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. B-Cell Lymphoma Current Treatment Patterns
4. B-Cell Lymphoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. B-Cell Lymphoma Late-Stage Products (Phase-III)
7. B-Cell Lymphoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. B-Cell Lymphoma Discontinued Products
13. B-Cell Lymphoma Product Profiles
14. B-Cell Lymphoma Key Companies
15. B-Cell Lymphoma Key Products
16. Dormant and Discontinued Products
17. B-Cell Lymphoma Unmet Needs
18. B-Cell Lymphoma Future Perspectives
19. B-Cell Lymphoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the B-Cell LymphomaO Pipeline Reports Offerings: https://www.delveinsight.com/report-store/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release B-Cell Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis, DelveInsight | Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi Biomedicine here
News-ID: 3818748 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Lymphoma
Lymphoma Treatment Market - Liberating Lives from Lymphoma: State-of-the-Art Tre …
Newark, New Castle, USA: The "Lymphoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Lymphoma Treatment Market: https://www.growthplusreports.com/report/lymphoma-treatment-market/8879
This latest report researches the industry structure, sales, revenue,…
Lymphoma Treatment Market - Inspiring Resilience, Shaping Survival: Innovations …
Newark, New Castle, USA - new report, titled Lymphoma Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Lymphoma Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Lymphoma Treatment market. The report offers an overview of the market, which…
Lymphoma Therapeutics Market: New Frontiers in Lymphoma Therapeutics | By AMR
Allied Market Research recently said Lymphoma is a type of cancer that affects the lymphatic system, which is an integral part of the body's immune system. While chemotherapy and radiation therapy have been the standard treatment options for lymphoma, recent advances in research have led to the development of new targeted therapies and immunotherapies.
♦ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/request-toc-and-sample/1448
One such targeted therapy is monoclonal antibodies, which can specifically target…
Daratumumab Market Precise Analysis , Forecast || key Players- Multiple Myeloma, …
Looking at the current market trends as well as the promising demand status of the “Daratumumab Market”, it can be projected that the future years will bring out positive outcomes. This research report added by Market Research Hub (MRH) on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application;…
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. T-Cell Lymphoma Market Analysis
2. Mechanism of T-Cell Lymphoma Therapeutics
3. T-Cell Lymphoma Drug Market Overview
3.1 Current Market Scenario
3.2 T Cell Lymphoma Clinical Pipeline Overview
4. T-Cell Lymphoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. T-Cell Lymphoma Drug Market Future Prospects
6. T-Cell Lymphoma Drug Clinical Pipeline By Company…
B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to B Cell Lymphoma
1.1 Outline
1.1.1 Non-Hodgkin’s Lymphoma
1.1.2 Hodgkin’s Lymphoma
1.2 Classification of the B Cell lymphoma
1.2.1 Diffuse Large B Cell Lymphoma
1.2.2 Follicular Lymphoma
1.2.3 Mantle Cell Lymphoma
1.2.4 Burkitt Lymphoma
1.3 Stages of…
